Long-term effects with ambrisentan monotherapy in patients with pulmonary arterial hypertension  

作　　者：文莉 

机构地区：[1]Dept Cardio-Pulm Cir,Shanghai Pulm Hosp,Med Sch,Tongji Univ

出　　处：《China Medical Abstracts(Internal Medicine)》2014年第3期160-161,共2页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To investigate long-term efficacy and safety of ambrisentan monotherapy in patients with pulmonary arterial hypertension(PAH).Methods Patients with PAH who received 2.5 mg or 5 mg of ambrisentan once daily between July 10,2011 and August 30,2012for at least 6 months were enrolled.The efficacy endpoints were changes in exercise capacity,World Health Organization(WHO)functional class and N-terminal probrain natriuretic peptide(NT-pro BNP)level,echocardiographic parameters.The safety endpoint was the safety of long-term ambrisentan administration,as defined

关 键 词：administration NATRIURETIC ENDPOINT enrolled exercise DIASTOLIC severity SYSTOLIC median baseline 

分 类 号：R544.1[医药卫生—心血管疾病]